Clinical and economic efficiency of treatment with cariprazine in schizophrenia

D’yakov I.N.; Zyrianov S.K.

doi:https://doi.org/10.17116/jnevro201911907169

Close metadata

Recommended articles:

The relationship between inflammatory markers, fatigue, and effort-based decision-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91

An individual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102

The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48

A role of transcription factors in pathogenic processes associated with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54

Metabolic syndrome and antipsychotic therapy of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170

Neuronal models based on olfactory epithelial cells in the study of the pathogenesis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):20-25

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34

Clinical and immunological relationships in patients with early schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Abstract:

Objective. To conduct a comprehensive pharmacoeconomic evaluation of feasibility of treatment with cariprazine (reagila) in patients with schizophrenia. Materials and methods. A retrospective study using the pharmacoeconomic cost analysis, budget impact analysis, and cost-effectiveness analysis was performed. Data on cariprazine were compared to those on sertindole. Results. If cariprazine is used instead of sertindole, the cost saved will amount to 30.8% per patient per year. If sertindole is fully replaced with cariprazine, the costs related to treatment of patients with a second generation antipsychotics funded by the state will be reduced by 97.8 million rubles over 3 years (30.9%). Gradual replacement of sertindole with cariprazine will make it possible to reduce budget expenditures by 20.1% or 63.8 million rubles over 3 years. This replacement will make it possible to provide therapy to additional 44.6% of patients, or 561 people. In this case, the number of patients receiving therapy will increase from 1257 to 1818. Conclusion. The results of the pharmacoeconomic analysis show that the registration of cariprazine (reagila) in the Russian Federation as therapeutic drug is economically feasible.

Keywords:

schizophrenia

atypical antipsychotics

negative symptoms

cariprazine

sertindol

budget

economic efficacy

Authors:

D’yakov I.N.

Mechnikov Research Institute of Vaccines and Sera

Zyrianov S.K.

Kafedra klinicheskoĭ farmakologii LF Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

Close metadata

References:

Dzhons PB, Bakli PF. Shizofreniya: Klinicheskoe rukovodstvo. Per. s angl. Pod red. Mosolova S.N. M. 2008 (In Russ.)
Mosolov SN. Some topical theoretical problems of diagnosis, classification, neurobiology, and therapy of schizophrenia: a comparison of foreign and domestic approaches. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2010;110:(6):4-11 (In Russ.)
Mosolov SN. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsiya pozitivnykh i negativnykh rasstroistv. M.: Novyi tsvet; 2001. (In Russ.)
Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506. https://doi.org/10.1176/appi.ajp.162.3.495
Potkin SG. Taking control of negative symptoms: The next step for improved patient outcomes in schizophrenia. APA 159^th Annual Meeting Industry-Supported Symposium 33, Guidebook. 2006;17-22.
Mosolov SN, Potapov AV, Shafarenko AA, Kostyukova AB, Ushakov YuV, Burygina LA, Zabelina IN. Development and validation of standardized remission criteria in schizophrenia. Modern Therapy for Mental Disorders. 2011;3:2-6. (In Russ.)
Mosolov SN, Potapov AV, Ushakov UV, Shafarenko AA, Kostyukova AB. Design and validation of standardized clinical and functional remission criteria in schizophrenia. Neuropsychiatric Disease and Treatment. 2014;10:167-181.
WHO. Mental Health and Development: Targeting People with Mental Health Conditions as a Vulnerable Group. World Health Organization Publication. 2010;1-65.
Psikhiatricheskaya pomoshch’ naseleniyu Rossiiskoi federatsii v 2015—2017 gg. Analiticheskii obzor pod red. Kekelidze Z.I. FGBU «FMITsPN im. V.P. Serbskogo» Minzdrava Rossii. M. 2018;142. (In Russ.)
Izmerov NF, Tikhonova GI, Gorchakova TYu. Mortality of the working-age population in Russia and developed nations of Europe: trends in the last twenty years. Annals of RAMS. 2014;7-8:121-112. (In Russ.)
Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics. 2008;26:2:149-162. https://doi.org/10.2165/00019053-200826020-00005
Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P. The burden of mental disorders. Epid Rev. 2008;30:1-14. https://doi.org/10.1093/epirev/mxn011
Goeree R, Farahati F, Burke N, Blackhouse G, O’Reilly D, Pyne J, Tarride J‐E. The economic burden of schizophrenia in Canada in 2004. Cur Med Res Opin. 2005;21(suppl 12):2017-2028. https://doi.org/10.1185/030079905X75087
Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(suppl 1):1-27. https://doi.org/10.1111/j.1468-1331.2005.01202.x
Gurovich IYa, Lyubov EB. Farmakoepidemiologiya i farmakoekonomika v psikhiatrii. M.: Medpraktika-M; 2003. (In Russ.)
Lyubov EB, Yastrebov VS, Shevchenko LS, Chapurin SA, Churilin YuYu, Bylim IA, Gazha AK, Doronin VV, Kosov AM, Petukhov YuL, Fadeev PN. Economic burden of schizophrenia in Russia. Social and Clinical Psychiatry. 2012;22:(3):36-42. (In Russ.)
Rossiiskii statisticheskii ezhegodnik — 2010 g. Federal’naya sluzhba gosudarstvennoi statistiki. Ofitsial’nyi internet-sait Rosstata (www.gks.ru). (In Russ.).
Ofitsial’nyi sait Rossiiskogo obshchestva psikhiatrov: https://psychiatr.ru/download/3904. Official website of Russian Society of Psychiatrists: https://psychiatr.ru/download/3904 (In Russ.)
Juckel G, de Bartolomeis A, Gorwood Ph, Mosolov S, Pani L, Rossi A, Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment. 2014;10:1867-1878. https://doi.org/10.2147/ndt.s61672
Mosolov SN, Tsukarzi EE, Alfimov PV. Algorithms of biological therapy for schizophrenia. Modern Therapy for Mental Disorders. 2014;1:27-36. (In Russ.)
Mosolov SN, Potapov AV, Ushakov UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Annals of General Psychiatry. 2012;11:1-12.
Alfimov PV, Mosolov SN. The role of dopamine D3-receptors in the mechanism of action of modern antipsychotics. Modern Therapy for Mental Disorders. 2014;1:2-9. (In Russ.)
Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9:2:193-206.
Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017;174(10):927-942. https://doi.org/10.1176/appi.ajp.2017.16121358
Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu shizofrenii. Pod red. Krasnova V.N. Rossiiskoe obshchestvo psikhiatrov. Moscow, 2013. Klinicheskie rekomendatsii. Diagnostika i lechenie shizofrenii. Rossiiskoe obshchestvo psikhiatrov. M. 2014. http://psychiatr.ru/download/1269? (In Russ.)
Psychopharmacotherapy of schizophrenia. In: Psychiatrics: National Guidelines. Eds. Neznanov N.G., Aleksandrovsky Yu.A. M. 2018;299-328. (In Russ.)
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103-1113. https://doi.org/10.1016/S0140-6736(17)30060-0
Durgam S, Cutler AJ, Kaifeng Lu, Migliore R, Ruth A, Laszlovszky I, Németh G, Herbert Y. Meltzer HY. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76:1574-1582. https://doi.org/10.4088/JCP.15m09997
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176:264-271. https://doi.org/10.1016/j.schres.2016.06.030
Instruction for Medical Use of medicinal product cariprazine (Reagila). https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=3a7c2f32-f659-4fdb-9d5c-f15f8f6b5c52&t= (In Russ.)
Muscatello MRA, Bruno A, Micali Bellinghieri P, Pandolfo G, Zoccali RA. Sertindole in schizophrenia: efficacy and safety issues. Expert Opinion on Pharmacotherapy. 2014;15(13):1943-1953. https://doi.org/10.1517/14656566.2014.947960
Mosolov SN, Kapiletti SG, Zhigareva NP, Shafarenko AA, Ryvkin PV, Kostyukova AB, Padkin SE. Long-term sertindole therapy of schizophrenia patients with primary negative symptoms. Modern Therapy for Mental Disorders. 2011;2:17-25. (In Russ.)
Metodicheskie rekomendatsii po otsenke vliyaniya na byudzhet v ramkakh realizatsii programmy gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi. M.: FGBU «Tsentr ekspertizy i kontrolya kachestva meditsinskoi pomoshchi»; 2016. (In Russ.)
Federal’noe rukovodstvo po ispol’zovaniyu lekarstvennykh sredstv (formulyarnaya sistema). Vypusk XIII. M. 2012. (In Russ.)
Instruction for Medical Use of medicinal product risperidone (Rileptid). https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=c08e55c9-4040-4d02-884e-765e735f0a34&t= (In Russ.)
Instruction for Medical Use of medicinal product quetiapine (Seroquel). https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=2ebd7d4d-702a-42c3-adf5-4e44f680c333&t= (In Russ.)
https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=aa848a1e-943b-4c31-a647-4afa1bb22335&t= (In Russ.)
Instruction for Medical Use of medicinal product olanzapine (Zyprexa). https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=28e18dd8-2393-4632-81e8-0de0fdb90a43&t= (In Russ.)
Instruction for Medical Use of medicinal product sertindole (Serdolect). https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=2581f955-ead8-4886-8057-c3f388939b71&t= (In Russ.)
Instruction for Medical Use of medicinal product paliperidone (Invega). https://grls.rosminzdrav.ru/Grls_View_v2.aspx.routingGuid=ef99adff-3945-4723-9ee7-8b1b1c691cc4&t= (In Russ.)
ATC/DDD Index 2019. https://www.whocc.no/atc_ddd_index/
Gosudarstvennyi reestr predel’nykh otpusknykh tsen. https://grls.rosminzdrav.ru/PriceLims.aspx. (In Russ.)
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Möller HJ, Mosolov SN. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia. Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. Modern Therapy for Mental Disorders. 2013;TB1:3-40. (In Russ.)
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Möller HJ, Mosolov SN. Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. Part 2. Modern Therapy for Mental Disorders. 2014;TB2:3-36 (In Russ.)
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller H-J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia — A short version for primary care. International Journal of Psychiatry in Clinical Practice. 2017;21:2:82-90. https://doi.org/10.1080/13651501.2017.1291839